Illumina, Inc. (ILMN): Price and Financial Metrics


Illumina, Inc. (ILMN)

Today's Latest Price: $376.35 USD

5.31 (1.43%)

Updated Jan 15 4:00pm

Add ILMN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 483 in Biotech

See all "A" rated Strong Buy stocks

ILMN Stock Summary

  • Illumina Inc's market capitalization of $54,171,840,000 is ahead of 95.69% of US-listed equities.
  • Price to trailing twelve month operating cash flow for ILMN is currently 48.5, higher than 90.21% of US stocks with positive operating cash flow.
  • ILMN's price/sales ratio is 16.73; that's higher than the P/S ratio of 88.66% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Illumina Inc are VMW, NTES, KLAC, EW, and ADI.
  • ILMN's SEC filings can be seen here. And to visit Illumina Inc's official web site, go to www.illumina.com.

ILMN Stock Price Chart Interactive Chart >

Price chart for ILMN

ILMN Price/Volume Stats

Current price $376.35 52-week high $404.20
Prev. close $371.04 52-week low $196.78
Day low $370.03 Volume 1,873,400
Day high $396.00 Avg. volume 1,202,190
50-day MA $340.29 Dividend yield N/A
200-day MA $339.75 Market Cap 54.95B

Illumina, Inc. (ILMN) Company Bio


Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. The company's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company was founded in 1998 and is based in San Diego, California.

ILMN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$376.35$103.59 -72%

We started the process of determining a valid price forecast for Illumina Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Illumina Inc ranked in the 24th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 72%. In terms of the factors that were most noteworthy in this DCF analysis for ILMN, they are:

  • The company's debt burden, as measured by earnings divided by interest payments, is 19.8; that's higher than 82.45% of US stocks in the Healthcare sector that have positive free cash flow.
  • The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than only 13.63% of the free cash flow producing stocks we're observing.
  • ILMN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 46.85% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-73%
1%-72%
2%-72%
3%-72%
4%-72%
5%-71%

DHR, ICUI, WAT, CDNA, and CNC can be thought of as valuation peers to ILMN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


ILMN Latest News Stream


Event/Time News Detail
Loading, please wait...

ILMN Latest Social Stream


Loading social stream, please wait...

View Full ILMN Social Stream

Latest ILMN News From Around the Web

Below are the latest news stories about Illumina Inc that investors may wish to consider to help them evaluate ILMN as an investment opportunity.

Fear of new virus variant pushes U.S. toward more genomic sequencing

The United Kingdom’s use of genomic sequencing to identify a more infectious strain of SARS-COV-2 has largely served as a wake-up call for inadequate use of the technology in the U.S.

Yahoo | January 15, 2021

Global Next Generation Sequencing Market Opportunities and Strategies Report 2020-2030 Featuring Illumina, Thermo Fisher Scientific, Agilent Technologies, Pacific Biosciences of California & QIAGEN - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Next Generation Sequencing Global Market Opportunities and Strategies 2020-30: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering. Next Generation Sequencing Global Market Opportunities and Strategies 2020-30: COVID-19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global next generation sequencing market. The global next generation sequencing

Business Wire | January 14, 2021

Global Cell Analysis Market (2020 to 2027) - Featuring Danaher, Illumina & Merck Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cell Analysis Global Market - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The cell analysis global market is expected to reach $33,542.0 million by 2027 growing at a mid-single-digit CAGR from 2020 to 2027. Cells constitute discrete units of biological function and serve as starting points in a myriad of studies to identify and map many of the basic biochemical and physical processes of life. Cell analysis is important to understan

Business Wire | January 14, 2021

New Strong Sell Stocks for January 14th

Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

Yahoo | January 14, 2021

mRNA Sequencing Market Size, Status and Forecast to 2025: Agilent Technologies, Roche, GE Healthcare, Illumina

The Global mRNA Sequencing Market has witnessed continuous growth in the past few years and may grow further during the forecast period (2020-2025). The assessment provides a 360° view and insights, outlining the key outcomes of the industry, current scenario

OpenPR | January 13, 2021

Read More 'ILMN' Stories Here

ILMN Price Returns

1-mo 2.81%
3-mo 17.15%
6-mo -3.46%
1-year 15.90%
3-year 55.96%
5-year 121.93%
YTD 1.72%
2020 11.53%
2019 10.61%
2018 37.27%
2017 70.64%
2016 -33.30%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7558 seconds.